Note: Neuropace's revenues are gauged from an analysis of company filings.
Neuropace has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
August 8, 2017
Complete list of funding rounds and total amounts in the Company Report
Neuropace's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Neuropace Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Neuropace is developing and marketing.
Neuropace's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
SIMPLESTART Operating software to be embedded in medical apparatus for treating neurological disorders
YOUR WINDOW TO THE BRAIN Medical devices, namely, apparatus for treatment of neurological disorders
TARGETED TREATMENT WHEN IT'S NEEDED medical devices, namely, apparatus for treatment of neurological disorders
Patent applications show Neuropace's intellectual property,
its current capabilities and future direction.
Neuropace has applied for 100 patents since 2009.
Neuropace's most recent patent was filed in February 2018 for Anatomically Compliant Antenna For Implantable Medical Device.A flexible antenna is associated with an active implantable medical device to facilitate communication between the implantable medical device and an external component in the outside world via, for example, long range or far field telemetry. The flexibility of the antenna allows it to conform to the shape of the location at which it is situated, such as on the cranial bone of a patient for an antenna associated with a cranially implanted medical device. The conformability of the antenna helps to maintain the antenna in the desired shape and to maintain it in the desired location relative to implantable medical device and the patient and improves patient comfort.
Complete list of patent applications
Determine whether Neuropace grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Neuropace is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: Neuropace vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as Neuropace, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Neuropace.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Neuropace and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.